A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
8/29/2025
BreakingPharmaRegulationRetina
US FDA Again Rejects Outlook’s Lytenava for Wet AMD, Citing Lack of Efficacy Evidence
Outlook Therapeutics reported Aug. 28 that the US FDA had issued a complete response letter rejecting the company’s resubmitted biologics license application (BLA) for Lytenava, an ophthalmic formu...
8/29/2025
BreakingEuropeGlaucomaMIGSRegulationSurgical
Ciliatech’s Intercil Uveal Spacer for Glaucoma Gains CE Marking
France’s Ciliatech announced Aug. 27 that European regulators had granted CE marking for the Intercil Uveal Spacer, a surgical implant for glaucoma. The Intercil, also known as the cilioscleral int...
8/29/2025
BreakingFundingOptometryRefractive
Eyebot to Expand Self-Serve Vision-Testing Kiosks with $20 Million Financing
Eyebot, of Boston, Massachusetts, plans to use the $20 million it raised in a Series A round in August 2025 to expand its vision testing kiosks to new retail locations. The kiosks—located in malls,...
8/29/2025
BiosimilarsBreakingDiagnosticDry EyeLaserMyopiaRetinaRevenue
Quarterly Ophthalmic Revenue Roundup for Santen, Lumibird, Biogen, and Xbrane
Japan’s Santen Pharmaceutical reported Aug. 7 that its revenue for the quarter ended June 30, 2025, the first quarter of its fiscal year, was ¥68.7 billion ($475.6 million, converted on June 30, 20...
8/29/2025
BreakingPharmaRegulationRetina
Manufacturer Inspection Report Delays Two Eylea HD Target Action Dates
Regeneron announced Aug. 20 that the US FDA had extended the target action dates to Q4-2025 for two Eylea HD (aflibercept 8 mg) submissions. Reports from a recent inspection of a third-party manufa...
8/29/2025
BreakingFundingGlaucomaStudy
Glaucoma Research Foundation to Use $5 Million Gift to Create Accelerator
The Glaucoma Research Foundation reported Aug. 20 that it plans to use a $5 million gift from the John and Daria Barry Foundation—the largest single donation in the foundation’s history—to launch t...
8/29/2025
BreakingRegulationRetina
US FDA Grants Fast Track Status to Aldeyra’s ADX‑2191 (Methotrexate) for RP
Aldeyra Therapeutics announced Aug. 19 that the US FDA had granted its fast track designation to ADX‑2191 (methotrexate intravitreal injection) for retinitis pigmentosa (RP). The candidate also has...
8/29/2025
BreakingGene TherapyRegulationRetina
US FDA Grants RMAT Status to VeonGen’s Gene Therapy Candidate in Stargardt
Germany’s VeonGen Therapeutics announced Aug. 21 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to VG801, its gene therapy candidate for Stargardt disease and...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.